|
|
 |
|
Sankyo Co., Ltd.: A Modern Company Built on Old World Traditions
For more than a century, Sankyo Co., Ltd., the Tokyo-based pharmaceutical company that owns Luitpold Pharmaceuticals, Inc., has been a world leader in the research, development, and manufacture of pharmaceuticals. Sankyo is one of the largest pharmaceutical companies in Japan. It was the first company to bring western medicines to Japan, and today the company continues to concentrate its research on the most serious health issues. Sankyo was the first to isolate epinephrine (adrenaline) and to identify Vitamin B1.
From the beginning, Sankyo has continued to be a major source of new and important drugs through innovative research. Its breakthrough drugs include medications for hypertension and cardiovascular disease, and it introduced a class of drugs called statins to the world. These cholesterol-lowering agents have revolutionized the field of cholesterol control.
Sankyo has had an equally important impact on the treatment of type 2 diabetes with its development of glitazones, a class of drugs which are believed to be vital in the long-term management of this disorder.
Sankyo Co., Ltd. and Luitpold Pharmaceuticals, Inc. remain committed to improving the health and lives of people in the United States. Through continued research, discovery, and development of new drug therapies — coupled with its unique ability to anticipate the ever-changing needs of medicine and pharmaceuticals — Sankyo and Luitpold will continue to create new and exciting therapies. |
|
